37000 GRAND RIVER AVE., FARMINGTON HILLS, MI
Earnings Release
Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases
R&D Science Forum June 16, 2026 | 10:00 AM – 12:00 PM ET
Announces Financial Results for First Quarter 2026 and Provides Corporate Update
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Opus Genetics Stockholders Elect Nine Directors and Ratify Auditor
Material Contracts, Unregistered Sales of Equity Securities, Reg. FD
News, Material Contracts
Q2
Q1
FY 2025
Q3
FY 2024
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus Filed Pursuant to Rule 424(b)(2)
Registration Statement for Securities to be Offered to Employees
Amended Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Additional Proxy Soliciting Materials
Definitive Additional Information Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Free Writing Prospectus
Correspondence